Selective dual orexin receptor antagonist approved for insomnia characterized by difficulty with sleep onset and/or sleep maintenance. Daridorexant (formerly nemorexant) reduces wakefulness during sleep by blocking orexin signaling.
Selective antagonism of both orexin-1 and orexin-2 receptors in the brain. Blocks orexin neuropeptide signaling, which maintains wakefulness, thereby promoting sleep onset and maintenance. More selective than traditional sedative-hypnotics.
Selective antagonism of both orexin-1 and orexin-2 receptors in the brain. Blocks orexin neuropeptide signaling, which maintains wakefulness, thereby promoting sleep onset and maintenance. More selective than traditional sedative-hypnotics.
© 2025[current_year] The Doctors Platform. All Right Reserved.
© 2025 The Doctors Platform. All Right Reserved.
